iTeos Therapeutics, Inc. (ITOS) |
|
11.51 0.15 (1.32%)
|
09-27 16:00 |
|
Open: |
11.41 |
Pre. Close: |
11.36 |
|
High:
|
11.66 |
Low:
|
11.39 |
|
Volume:
|
173,972 |
Market Cap:
|
412(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:20:13 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 17.86 One year: 20.94 |
| Support: |
Support1: 11.03 Support2: 9.18 |
| Resistance: |
Resistance1: 15.29 Resistance2: 17.93 |
| Pivot: |
12.13  |
| Moving Average: |
MA(5): 11.49 MA(20): 12.21
MA(100): 13.53 MA(250): 16.18 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 14.3 %D(3): 10.2 |
| RSI: |
RSI(14): 40.1 |
| 52-week: |
High: 23 Low: 11.03 |
| Average Vol(K): |
3-Month: 381 (K) 10-Days: 223 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ITOS ] has closed above bottom band by 19.8%. Bollinger Bands are 12.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.68 - 11.74 |
11.74 - 11.79 |
|
Low:
|
11.25 - 11.32 |
11.32 - 11.38 |
|
Close:
|
11.4 - 11.51 |
11.51 - 11.61 |
|
Company Description |
|
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. |
Headline News |
Mon, 25 Sep 2023
CAR T-cell Therapy for Multiple Myeloma Market to Observe ... - PR Newswire
Wed, 20 Sep 2023
iTeos Therapeutics, Inc. Faces Challenges Despite Positive ... - Best Stocks
Wed, 06 Sep 2023
iTeos to Participate in Upcoming Investor Conferences - GlobeNewswire
Tue, 05 Sep 2023
Citigroup Inc. Increases Holdings in iTeos Therapeutics ... - Best Stocks
Wed, 23 Aug 2023
Healthcare Stocks Moving Wednesday: APLS, ITOS, BNOX, ADTX, TIVC, ZJYL, EYPT, DH - InvestorsObserver
Wed, 23 Aug 2023
Gilead, Arcus, iTeos, other biopharmas get boost from accidental ... - Morningstar
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
36 (M) |
| Shares Float |
25 (M) |
|
% Held by Insiders
|
0.3 (%) |
|
% Held by Institutions
|
104.4 (%) |
|
Shares Short
|
1,620 (K) |
|
Shares Short P.Month
|
1,410 (K) |
Stock Financials |
|
EPS
|
-0.81 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
17.43 |
|
Profit Margin (%)
|
-33.1 |
|
Operating Margin (%)
|
-74.6 |
|
Return on Assets (ttm)
|
-5.3 |
|
Return on Equity (ttm)
|
-4.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
7.47 |
|
Sales Per Share
|
2.4 |
|
EBITDA (p.s.)
|
-1.77 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-113 (M) |
|
Levered Free Cash Flow
|
-114 (M) |
Stock Valuations |
|
PE Ratio
|
-14.39 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0.66 |
|
Price to Sales
|
4.78 |
|
Price to Cash Flow
|
-3.65 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
